A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP – Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $5.00 target ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome ...

Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) by 15.9% in the fourth quarter, according to the company in its most ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery ...

2025-03-23报道，近日，中国医学科学院肿瘤医院王洁、白桦等研究者在Signal Transduction and Targeted ...

The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation ... inhibitor of the MDM2-p53 protein-protein ...

Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...

We are pleased to welcome Preetam to Elicio’s executive team,” said Robert Connelly, Ph.D., President and Chief Executive Officer of Elicio. “He joins us during an exciting time. We remain encouraged ...

By analyzing huge amounts of biological data, the use of machine learning accelerates the identification of critical control ...